After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

For years, Dexcom has been one of the leading competitors in the continuous glucose monitoring space. While the company is focused on looking ahead, that’s not to say there haven’t been some bumps in ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.

Dexcom G6 is the first Continuous Glucose Monitoring (CGM) System to be listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a leader in ...